EX-99.1 3 dex991.htm PRESS RELEASE DATED JULY 21,2003 Press Release dated July 21,2003

EXHIBIT 99.1

 

Exponent Reports Second Quarter 2003 Results


 

MENLO PARK, Calif., July 21, 2003—Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the second quarter ended July 4, 2003.

 

In the second quarter of 2003, net income increased by 26% to $2,674,000, or $0.34 per diluted share, compared to $2,123,000, or $0.28 per diluted share for the same period a year ago. Revenues were $34,922,000, an increase of 10%, versus $31,632,000 for the same period a year ago.

 

For the first half of 2003, net income increased by 27% to $5,143,000, or $0.65 per diluted share, compared to $4,042,000, or $0.54 per diluted share, for the same period in 2002. Revenues were $69,737,000, an increase of 12%, versus $62,244,000 for the same period a year ago.

 

“We are pleased to report record quarterly revenues and net income. We experienced strong growth in our Technology Development, Civil, Toxicology and Mechanics and Materials practices,” commented President and CEO, Michael R. Gaulke. “During the quarter Technology Development delivered additional integrated robots and controllers to assist the U.S. Army in exploring caves and searching buildings. Our engineering field support teams in Iraq and Afghanistan have been supporting the Rapid Equipping Force in developing and deploying technologies to soldiers in the field. Additionally, we worked on the fourth phase of the Advanced Combat Uniform project, which included the prototyping of our proposed design for the next generation of soldier ensemble.”

 

Mr. Gaulke continued, “We continued our strategic focus in pursuit of a leadership position in health science consulting. During the quarter we continued to be involved in the scientific aspects of litigation involving alleged health hazards of asbestos in products, such as floor tiles, roofing materials, glues and brake pads. Additionally, the integration of our new Food and Chemicals practice, formerly Novigen Sciences which was acquired in May of 2002, continued to contribute to the growth of this segment of our business.”

 

Exponent is an engineering and scientific consulting firm providing solutions to complex problems. Exponent’s multidisciplinary organization of scientists, physicians, engineers, and business consultants brings together more than 70 technical disciplines to address complicated issues facing industry and government today. The firm’s consultants analyze failures and accidents to determine their causes and provide answers to help prevent such problems. In addition, Exponent evaluates human health and environmental concerns to find cost-effective solutions.

 

Exponent may be reached at (888) 656-EXPO, mailto:info@exponent.com, or www.exponent.com.

 

- more -

 


This news release contains, and incorporates by reference, certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended thereto under) that are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. When used in this document and in the documents incorporated herein by reference, the words “anticipate,” “believe,” “estimate,” “expect” and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include those discussed in our Annual Report on Form 10-K under the heading “Factors That May Affect Future Operating Results and Market Price of Stock” and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.

 

- more -

 


EXPONENT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Quarters and Six Months Ended July 4, 2003 and June 28, 2002

(in thousands, except per share data)


 

     Quarters Ended

   Six Months Ended

     July 4,
2003


   June 28,
2002


   July 4,
2003


   June 28,
2002


Revenues

                           

Revenues before reimbursements

   $ 31,808    $ 28,894    $ 63,279    $ 57,125

Reimbursements

     3,114      2,738      6,458      5,119
    

  

  

  

Revenues

     34,922      31,632      69,737      62,244

Operating expenses

                           

Compensation and related expenses

     20,713      18,923      41,315      37,401

Other operating expenses

     4,522      4,321      9,181      8,354

Reimbursable expenses

     3,114      2,738      6,458      5,119

General and administrative expenses

     2,065      2,032      4,186      3,850
    

  

  

  

       30,414      28,014      61,140      54,724
    

  

  

  

Operating income

     4,508      3,618      8,597      7,520

Other income

                           

Interest income, net

     13      40      24      60

Miscellaneous income, net

     209      98      480      190
    

  

  

  

       222      138      504      250
    

  

  

  

Income before income taxes

     4,730      3,756      9,101      7,770

Income taxes

     2,056      1,633      3,958      3,728
    

  

  

  

Net income

   $ 2,674    $ 2,123    $ 5,143    $ 4,042
    

  

  

  

Net income per share:

                           

Basic

   $ 0.37    $ 0.32    $ 0.72    $ 0.61

Diluted

   $ 0.34    $ 0.28    $ 0.65    $ 0.54

Shares used in per share computations:

                           

Basic

     7,215      6,739      7,164      6,642

Diluted

     7,932      7,480      7,862      7,420

 


EXPONENT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

July 4, 2003 and January 3, 2003

(in thousands)


 

     July 4,
2003


    January 3,
2003


 

Assets

                

Current assets:

                

Cash and cash equivalents

   $ 26,050     $ 22,480  

Accounts receivable, net

     40,243       38,404  

Prepaid expenses and other assets

     1,741       3,450  

Deferred income taxes

     1,928       1,928  
    


 


Total current assets

     69,962       66,262  
    


 


Property, equipment and leasehold improvements, net

     31,331       31,712  

Goodwill

     8,573       8,567  

Other assets

     620       675  
    


 


     $ 110,486     $ 107,216  
    


 


Liabilities and Stockholders’ Equity

                

Current liabilities:

                

Accounts payable and accrued liabilities

   $ 3,301     $ 5,183  

Current installments of long-term obligations

     61       205  

Accrued payroll and employee benefits

     14,002       14,667  

Deferred revenues

     858       1,511  
    


 


Total current liabilities

     18,222       21,566  
    


 


Long-term obligations, net of current installments

     197       167  

Deferred income taxes

     860       860  

Deferred rent

     935       837  
    


 


Total liabilities

     20,214       23,430  
    


 


Stockholders’ equity:

                

Common stock

     8       8  

Additional paid-in capital

     34,228       33,898  

Accumulated other comprehensive income (loss)

     26       (39 )

Retained earnings

     61,441       56,298  

Treasury shares, at cost

     (5,431 )     (6,379 )
    


 


Total stockholders’ equity

     90,272       83,786  
    


 


     $ 110,486     $ 107,216